Piper Jaffray Downgrades Osiris Therapeutics (OSIR) to Neutral; Disappointing Top-Line Data From Phase III Trials
Tweet Send to a Friend
Piper Jaffray & Co. downgrades Osiris Therapeutics (Nasdaq: OSIR) to Neutral. Price target slashed from $18 to $7.
Piper analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
